We are committed to strategic growth through targeted product development.

Smart Immune actively pursues co-development opportunities that add significant value to its pipeline and are relevant to its areas of expertise: thymus-educated T-cell progenitor-derived cell and gene therapies, with an increasing range of applications including hematological malignancies, primary immune deficiencies, and immune-oncology.
‍
Please direct business development inquiries to:
‍
‍partnering@smart-immune.com